1. Home
  2. STKS vs CING Comparison

STKS vs CING Comparison

Compare STKS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

HOLD

Current Price

$1.83

Market Cap

58.4M

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.09

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
CING
Founded
2004
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.4M
64.5M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
STKS
CING
Price
$1.83
$5.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$4.70
$34.50
AVG Volume (30 Days)
16.4K
146.4K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.47
EPS
N/A
N/A
Revenue
$805,722,000.00
N/A
Revenue This Year
$7.47
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.66
N/A
52 Week Low
$1.65
$3.16
52 Week High
$3.38
$11.89

Technical Indicators

Market Signals
Indicator
STKS
CING
Relative Strength Index (RSI) 52.99 46.89
Support Level $1.69 $4.80
Resistance Level $1.97 $5.20
Average True Range (ATR) 0.09 0.25
MACD 0.01 0.02
Stochastic Oscillator 77.27 51.57

Price Performance

Historical Comparison
STKS
CING

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: